Drug intelligence / Profile preview

LYB004

Development stage: Phase 2
Lead developer: Guangzhou Patronus Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LYB004 is a recombinant zoster vaccine being developed for the prevention of herpes zoster (shingles) infections. It is administered through intramuscular injection and is being developed based on Universal Virus-like Particles (U-VLP) technology platform. The vaccine is currently undergoing Phase I clinical trials to evaluate its safety and immunogenicity in adults.

Other names: Recombinant Zoster Vaccine (CHO Cell)

Targets

gE (VZV glycoprotein E)

Beyond the preview

Go deeper on LYB004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYB004.

Explore the full profile